Clinical Trials Browser

Interventional × ficlatuzumab × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Neoplasm Metastasis, Recurrence

NCT03422536 2024-09-04

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03316599 2021-08-03

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Phase 1 Completed

26 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT02318368 2020-10-22

FOCAL

Phase 2 Terminated

10 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04100330 2020-03-31

CyFi2

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02109627 2020-03-24

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Phase 1 Terminated

17 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02277197 2019-04-18

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Phase 1 Completed

14 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02277184 2017-11-13

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 1 Terminated

1 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma

NCT01039948 2015-04-08

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Phase 1/2 Completed

203 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT00725634 2014-01-27

P05538

Phase 1 Completed

41 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasms, Plasma Cell

NCT00969410 2012-04-12

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

Phase 1 Completed

19 enrolled

Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes

NCT01189513 2012-02-20

SCH-900105 in Recurrent Glioblastoma

Phase 1 Withdrawn

CNSSarcoma

Glioblastoma, Gliosarcoma

Clinical Trials

FIERCE-HN

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

FOCAL

CyFi2

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

P05538

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

SCH-900105 in Recurrent Glioblastoma